A review of six placebo-controlled scientific trials with 1,134 complete participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were affiliated with a increased common enhancement around the Ashworth scale for spasticity in a number of sclerosis people in contrast with placebo, Though this did not attain statistical importan